Detalhe da pesquisa
1.
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Cardiovasc Diabetol
; 20(1): 6, 2021 01 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33413355
2.
Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study.
Bone Rep
; 16: 101175, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35242892
3.
Long COVID-19: Objectifying most self-reported neurological symptoms.
Ann Clin Transl Neurol
; 9(2): 141-154, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35060361
4.
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.
ESC Heart Fail
; 9(4): 2233-2238, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35611683
5.
[Indications of antidiabetic drugs beyond glucose control]. / Indikationen von Antidiabetika jenseits der Glukosekontrolle.
MMW Fortschr Med
; 165(5): 42-49, 2023 03.
Artigo
Alemão
| MEDLINE | ID: mdl-36894856